Evidence map›Paper›PMID 32917816›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2020

Regulation of hepatic insulin signaling and glucose homeostasis by sphingosine kinase 2.

Gulibositan Aji, Yu Huang, Mei Li Ng, Wei Wang, Tian Lan, Min Li, Yufei Li, Qi Chen, Rui Li, Sishan Yan and 14 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 47 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Opaganib Promotes Weight Loss and Suppresses High-Fat Diet-Induced Obesity and Glucose Intolerance.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025
    Article
  7. FGF1 as a New Promising Therapeutic Target in Type 2 Diabetes: Advances in Research and Clinical Trials.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025
    Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Sphingosine 1-Phosphate Regulates Obesity and Glucose Homeostasis.International journal of molecular sciences · 2024
    Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Sphingosine kinase 2 regulates insulin receptor trafficking in hepatocytes.Experimental biology and medicine (Maywood, N.J.) · 2023
    Article
  18. Article
  19. Mechanism and therapeutic strategy of hepaticWorld journal of gastroenterology · 2022
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 3 institutions in 3 countries.

Gulibositan AjiDepartment of Endocrinology and Metabolism, Fudan Institute for Metabolic Diseases, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Yu HuangCentenary Institute, The University of Sydney, Sydney, NSW 2050, Australia.
Mei Li NgCentenary Institute, The University of Sydney, Sydney, NSW 2050, Australia.ORCID 0000-0001-9917-4534
Wei WangDepartment of Endocrinology and Metabolism, Fudan Institute for Metabolic Diseases, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Tian LanSchool of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, China.
Min LiCentenary Institute, The University of Sydney, Sydney, NSW 2050, Australia.
Yufei LiDepartment of Endocrinology and Metabolism, Fudan Institute for Metabolic Diseases, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Qi ChenDepartment of Endocrinology and Metabolism, Fudan Institute for Metabolic Diseases, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Rui LiSchool of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, China.
Sishan YanSchool of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, China.
Collin TranCentenary Institute, The University of Sydney, Sydney, NSW 2050, Australia.
James G BurchfieldSchool of Life and Environmental Sciences, The University of Sydney, Sydney, NSW 2006, Australia.ORCID 0000-0002-6609-6151
Timothy A CouttasCentenary Institute, The University of Sydney, Sydney, NSW 2050, Australia.ORCID 0000-0002-5896-2638
Jinbiao ChenCentenary Institute, The University of Sydney, Sydney, NSW 2050, Australia.ORCID 0000-0003-0339-5880
Long Hoa ChungCentenary Institute, The University of Sydney, Sydney, NSW 2050, Australia.
Da LiuCentenary Institute, The University of Sydney, Sydney, NSW 2050, Australia.ORCID 0000-0003-3994-2786
Carol WadhamCentenary Institute, The University of Sydney, Sydney, NSW 2050, Australia.
Philip J HoggCentenary Institute, The University of Sydney, Sydney, NSW 2050, Australia.
Xin GaoDepartment of Endocrinology and Metabolism, Fudan Institute for Metabolic Diseases, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Mathew A VadasCentenary Institute, The University of Sydney, Sydney, NSW 2050, Australia.
Jennifer R GambleCentenary Institute, The University of Sydney, Sydney, NSW 2050, Australia.
Anthony S DonCentenary Institute, The University of Sydney, Sydney, NSW 2050, Australia.ORCID 0000-0003-1655-1184
Pu XiaDepartment of Endocrinology and Metabolism, Fudan Institute for Metabolic Diseases, Zhongshan Hospital, Fudan University, Shanghai 200032, China; j.qi@centenary.org.au xia.pu@zs-hospital.sh.cn.ORCID 0000-0003-4705-8878
Yanfei QiCentenary Institute, The University of Sydney, Sydney, NSW 2050, Australia; j.qi@centenary.org.au xia.pu@zs-hospital.sh.cn.ORCID 0000-0003-1391-4111
The University of Sydney · AUFudan University · CNGuangdong Pharmaceutical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sphingolipid dysregulation is often associated with insulin resistance, while the enzymes controlling sphingolipid metabolism are emerging as therapeutic targets for improving insulin sensitivity. We report herein that sphingosine kinase 2 (SphK2), a key enzyme in sphingolipid catabolism, plays a critical role in the regulation of hepatic insulin signaling and glucose homeostasis both in vitro and in vivo. Hepatocyte-specific

Indexed as

AnimalsCell Line, TumorFemaleGlucoseHepatocytesHomeostasisHumansInsulinLiverMaleMiceMice, KnockoutPhosphatidylinositol 3-KinasesPhosphotransferases (Alcohol Group Acceptor)SphingolipidsSphingosine KinaseGlucoseInsulinPhosphatidylinositol 3-KinasesPhosphotransferases (Alcohol Group Acceptor)SphingolipidsSphingosine Kinasesphingosine kinase 2, mouseSphk1 protein, mouseceramidehepatocyteinsulin resistancesphingolipidstype 2 diabetes

Identifiers

PMID32917816
PMCPMC7533871
OpenAlexW3086517918

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.